论文部分内容阅读
目的观察口服降糖药磷酸西格列汀对2型糖尿病患者的临床疗效及安全性。方法对50例血糖控制欠佳的2型糖尿病患者进行为期12周的磷酸西格列汀治疗观察,分别于治疗前及治疗半个月后、1个月后、2个月后、3个月后测定患者的空腹血糖(FBG)、餐后2 h血糖、胰高血糖素、血常规、血压、肝肾功能、腰围,治疗3个月后测糖化血红蛋白(HbA1C)。结果磷酸西格列汀治疗1、2、3个月后空腹血糖及餐后2 h血糖、胰高血糖素水平均较治疗前明显下降(P<0.05或0.01),3个月后糖化血红蛋白明显下降(P<0.05)。血压、肝肾功能、血常规及腰围无明显变化(均P>0.05)。结论磷酸西格列汀有明显降低2型糖尿病患者空腹血糖、餐后血糖、糖化血红蛋白及抑制α细胞活性的作用,同时无明显副作用,是治疗2型糖尿病有效且安全的口服降糖药。
Objective To observe the clinical efficacy and safety of oral hypoglycemic agents such as sitagliptin in patients with type 2 diabetes mellitus. Methods Fifty patients with type 2 diabetes with poor glycemic control were treated with sitagliptin phosphate for 12 weeks. Before and after treatment for half a month, after one month, two months and three months The fasting blood glucose (FBG), postprandial blood glucose, glucagon, blood pressure, blood pressure, liver and kidney function and waist circumference were measured before and 3 months after treatment. HbA1C was measured. Results Fasting blood glucose and postprandial 2-hour postprandial blood glucose and glucagon levels were significantly decreased after treatment with sitagliptin phosphate for 1, 2 and 3 months (P <0.05 or 0.01), and glycosylated hemoglobin was significantly increased after 3 months Decreased (P <0.05). Blood pressure, liver and kidney function, blood and waist no significant changes (all P> 0.05). Conclusion Sogliptin phosphate can significantly reduce the fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin and inhibit the activity of α-cell in patients with type 2 diabetes, and has no obvious side effects. It is an effective and safe oral hypoglycemic agent for type 2 diabetes mellitus.